Literature DB >> 29725532

Clinical significance of random bladder biopsy in primary T1 bladder cancer.

Masafumi Otsuka1, Satoru Taguchi1, Tohru Nakagawa1, Teppei Morikawa2, Shigekatsu Maekawa2, Jimpei Miyakawa1, Akihiko Matsumoto1, Hideyo Miyazaki1, Tetsuya Fujimura1, Hiroshi Fukuhara1, Haruki Kume1, Yasuhiko Igawa3, Yukio Homma1.   

Abstract

The clinical significance of random bladder biopsies in primary non-muscle-invasive bladder cancer is unclear. The present study investigated the significance of positive random bladder biopsies in primary T1 NMIBC. The present study retrospectively reviewed the records of 71 patients with primary pT1N0M0 bladder cancer who underwent transurethral resection of the bladder tumor (TURBT) and concomitant random bladder biopsy. A total of 12 patients who received cystectomy immediately following the TURBT were excluded, and the remaining 59 patients were included in the analysis. Random bladder biopsy was defined as a cold-cup biopsy of pre-specified normal-looking areas in the bladder. The association of clinicopathological factors, including random biopsy results, with intravesical recurrence were assessed by univariate and multivariate Cox proportional hazards analyses. Of the 59 patients, 15 (25%) demonstrated carcinoma in situ (CIS) lesions on random bladder biopsy: Five (33%) in biopsy specimens alone and the remaining 10 (67%) in biopsy and TUR specimens. Positive random biopsy was associated with preoperative positive urine cytology (P=0.011) and small size of the main tumor (P=0.008). Multivariate analysis demonstrated positive random biopsy as the sole independent poor prognostic factor for intravesical recurrence (hazard ratio: 4.69, P=0.014). The five patients who had CIS detected in biopsy specimens alone had worse, although non-significantly worse, recurrence-free survival compared with those with CIS detected in biopsy and TUR specimens (P=0.100). In conclusion, positive bladder random biopsy, equivalent to the presence of CIS, was an independent predictor of recurrence in primary T1 bladder cancer. Given that one-third of CIS lesions could not have been detected without biopsy, random bladder biopsy should be considered for patients with T1 tumors.

Entities:  

Keywords:  bladder cancer; carcinoma in situ; non-muscle-invasive bladder cancer; random bladder biopsy; recurrence

Year:  2018        PMID: 29725532      PMCID: PMC5920156          DOI: 10.3892/mco.2018.1587

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  22 in total

1.  Increased lung and bladder cancer incidence in adults after in utero and early-life arsenic exposure.

Authors:  Craig Steinmaus; Catterina Ferreccio; Johanna Acevedo; Yan Yuan; Jane Liaw; Viviana Durán; Susana Cuevas; José García; Rodrigo Meza; Rodrigo Valdés; Gustavo Valdés; Hugo Benítez; Vania VanderLinde; Vania Villagra; Kenneth P Cantor; Lee E Moore; Saida G Perez; Scott Steinmaus; Allan H Smith
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-05-23       Impact factor: 4.254

2.  Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.

Authors:  Joan Palou; Richard J Sylvester; Oscar Rodríguez Faba; Rubén Parada; Juan A Peña; Ferran Algaba; Humberto Villavicencio
Journal:  Eur Urol       Date:  2011-10-25       Impact factor: 20.096

Review 3.  Epidemiology and risk factors of urothelial bladder cancer.

Authors:  Maximilian Burger; James W F Catto; Guido Dalbagni; H Barton Grossman; Harry Herr; Pierre Karakiewicz; Wassim Kassouf; Lambertus A Kiemeney; Carlo La Vecchia; Shahrokh Shariat; Yair Lotan
Journal:  Eur Urol       Date:  2012-07-25       Impact factor: 20.096

Review 4.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

Authors:  Marko Babjuk; Maximilian Burger; Richard Zigeuner; Shahrokh F Shariat; Bas W G van Rhijn; Eva Compérat; Richard J Sylvester; Eero Kaasinen; Andreas Böhle; Joan Palou Redorta; Morgan Rouprêt
Journal:  Eur Urol       Date:  2013-06-12       Impact factor: 20.096

5.  Clinical evaluation of random biopsy of urinary bladder in patients with superficial bladder cancer.

Authors:  I Taguchi; K Gohji; I Hara; A Gotoh; Y Yamada; K Yamanaka; H Okada; S Arakawa; S Kamidono
Journal:  Int J Urol       Date:  1998-01       Impact factor: 3.369

6.  Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion.

Authors:  Patrik Andius; Sonny L Johansson; Sten Holmäng
Journal:  Urology       Date:  2007-10       Impact factor: 2.649

7.  Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients.

Authors:  Stefan Denzinger; Wolfgang Otto; Hans-Martin Fritsche; Wolfgang Roessler; Wolf F Wieland; Arndt Hartmann; Maximilian Burger
Journal:  Int J Urol       Date:  2007-11       Impact factor: 3.369

8.  Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy.

Authors:  Jörg Schmidbauer; Fred Witjes; Nikolaus Schmeller; Roland Donat; Martin Susani; Michael Marberger
Journal:  J Urol       Date:  2004-01       Impact factor: 7.450

9.  A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.

Authors:  Yves Fradet; H Barton Grossman; Leonard Gomella; Seth Lerner; Michael Cookson; David Albala; Michael J Droller
Journal:  J Urol       Date:  2007-05-11       Impact factor: 7.450

10.  Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases.

Authors:  Tomohiko Hara; Mutsuo Takahashi; Toshikazu Gondo; Kazuhiro Nagao; Chietaka Ohmi; Shigeru Sakano; Katsusuke Naito; Hideyasu Matsuyama
Journal:  Int J Urol       Date:  2009-01-20       Impact factor: 3.369

View more
  1 in total

1.  Definitive BCG immunotherapy versus radical cystectomy in intermediate or high-risk nonmuscle invasive bladder cancer patients: A retrospective study.

Authors:  Xiaoming Jian; Mingkang Shen; Guodong Liao
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.